Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Single-center, Open-label, Phase 1 Study Consisting of a Single-dose Pilot Phase and a Randomized, Two-way Crossover, Single-dose Main Phase to Investigate the Absolute Bioavailability of a Single Oral Dose of Selexipag in Healthy Male Subjects

NCT02882425 is registered in ClinicalTrials.gov with Actelion as lead sponsor.

NCT NCT02882425
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02882425 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Single-center, Open-label, Phase 1 Study Consisting of a Single-dose Pilot Phase and a Randomized, Two-way Crossover, Single-dose Main Phase to Investigate the Absolute Bioavailability of a Single Oral Dose of Selexipag in Healthy Male Subjects
Lead sponsor
Actelion
Phase
Phase 1
Overall status
Completed
Start date
January 31, 2015
Completion date
April 30, 2015
Enrollment
19 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

healthy subjects